According to Zacks, analysts expect that Novocure will report full-year earnings of ($0.67) per share for the current financial year. For the next year, analysts anticipate that the company will report earnings of ($0.44) per share, with EPS estimates ranging from ($0.77) to ($0.23). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Novocure.
Wall Street brokerages forecast that Novocure Ltd (NASDAQ:NVCR) will report earnings of ($0.15) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Novocure’s earnings. Novocure reported earnings of ($0.12) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 25%. The firm is scheduled to announce its next quarterly earnings report before the market opens on Thursday, February 28th.
Novocure (NASDAQ:NVCR) last announced its quarterly earnings data on Thursday, February 28th. The medical equipment provider reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). Novocure had a negative net margin of 25.62% and a negative return on equity of 57.09%.
A number of research analysts have recently weighed in on NVCR shares. Zacks Investment Research raised Novocure from a “sell” rating to a “hold” rating in a research note on Wednesday, February 20th. Wells Fargo & Co reissued a “hold” rating on shares of Novocure in a research note on Thursday, February 28th. BidaskClub raised Novocure from a “hold” rating to a “buy” rating in a research note on Friday, January 11th. Mizuho reissued a “buy” rating and issued a $51.00 price target on shares of Novocure in a research note on Thursday, November 15th. Finally, ValuEngine raised Novocure from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $49.71.
In related news, CEO Asaf Danziger sold 903 shares of the firm’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $54.40, for a total transaction of $49,123.20. Following the sale, the chief executive officer now owns 233,757 shares of the company’s stock, valued at approximately $12,716,380.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael J. Ambrogi sold 100,000 shares of the firm’s stock in a transaction on Wednesday, January 9th. The stock was sold at an average price of $40.00, for a total value of $4,000,000.00. Following the sale, the chief operating officer now directly owns 221,558 shares in the company, valued at approximately $8,862,320. The disclosure for this sale can be found here. Insiders have sold a total of 1,126,687 shares of company stock worth $52,326,450 in the last ninety days. 15.30% of the stock is currently owned by company insiders.
Institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP acquired a new stake in Novocure during the 3rd quarter worth $1,323,000. Credit Suisse AG raised its stake in Novocure by 87.2% during the 3rd quarter. Credit Suisse AG now owns 945,654 shares of the medical equipment provider’s stock worth $49,552,000 after buying an additional 440,543 shares during the period. FMR LLC raised its stake in Novocure by 37.9% during the 3rd quarter. FMR LLC now owns 10,845,246 shares of the medical equipment provider’s stock worth $568,292,000 after buying an additional 2,983,125 shares during the period. First Republic Investment Management Inc. acquired a new stake in shares of Novocure in the 3rd quarter valued at about $1,609,000. Finally, Rhenman & Partners Asset Management AB raised its stake in shares of Novocure by 36.3% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 545,000 shares of the medical equipment provider’s stock valued at $18,247,000 after purchasing an additional 145,000 shares during the period. 61.47% of the stock is currently owned by institutional investors and hedge funds.
NVCR stock opened at $51.41 on Monday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 4.63 and a current ratio of 4.98. The firm has a market capitalization of $4.85 billion, a PE ratio of -73.44 and a beta of 3.24. Novocure has a twelve month low of $19.55 and a twelve month high of $56.67.
Novocure Company Profile
Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St.
Further Reading: How Buying a Call Option Works
Get a free copy of the Zacks research report on Novocure (NVCR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com